Exact Mass: 469.1215
Exact Mass Matches: 469.1215
Found 225 metabolites which its exact mass value is equals to given mass value 469.1215
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Indol-3-ylacetyl-myo-inositol L-arabinoside
RO4929097
D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
O-Methyl-4-[(2',3',4'-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]thiocarbamate
O-Methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]thiocarbamate is a fully acetylated thiocarbamate glycoside. It has been isolated from the leaves of Moringa oleifera (horseradish tree). It is found in fats and oils, herbs and spices, and green vegetables. The trans and cis rotamers differ in the orientation of the NH group with respect to sulfur.
(beta-1-O-[N-(2-hydroxymethyl-3-chlorophenyl)anthraniloyl]-D-glucupyranuronic acid)
(beta-1-O-[N-(2-hydroxymethyl-3-chlorophenyl)anthraniloyl]-D-glucupyranuronic acid) belongs to the family of Glucuronides. These are compounds comprising the glucuronic acid linked to another substance via a glycosidic bond.
N-(2-(3-(Piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide
SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
Bucladesine
Dacomitinib
Ethanol and folate
Oxaprozin glucuronide
RO4929097
D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators
Thalictrine Iodide
(+)-Magnoflorine iodide (Magnoflorine iodide), an aporphine alkaloid found in Acoruscalamus, reduces the formation of C. albicans biofilm[1]. (+)-Magnoflorine iodide has anti-fungal, anti-antidiabetic and anti-oxidative activity[2]. (+)-Magnoflorine iodide (Magnoflorine iodide), an aporphine alkaloid found in Acoruscalamus, reduces the formation of C. albicans biofilm[1]. (+)-Magnoflorine iodide has anti-fungal, anti-antidiabetic and anti-oxidative activity[2].
2-[1-[4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]indol-3-yl]acetic acid
O-methyl-4-<(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl>thiocarbamate (E)|O-methyl-4-<(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl>thiocarbamate (Z)|O-methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl]thiocarbamate (E)|O-methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl]thiocarbamate (Z)
5-O-beta-D-glucopyranosyl-dihydroABG|5-O-beta-D-glucopyranosyl-dihydroascorbigen
CAY10576
Bucladesine
C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CE - Phosphodiesterase inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
SRT 1720
SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
Thalictrine Iodide
(+)-Magnoflorine iodide (Magnoflorine iodide), an aporphine alkaloid found in Acoruscalamus, reduces the formation of C. albicans biofilm[1]. (+)-Magnoflorine iodide has anti-fungal, anti-antidiabetic and anti-oxidative activity[2]. (+)-Magnoflorine iodide (Magnoflorine iodide), an aporphine alkaloid found in Acoruscalamus, reduces the formation of C. albicans biofilm[1]. (+)-Magnoflorine iodide has anti-fungal, anti-antidiabetic and anti-oxidative activity[2].
Ala Cys Asn Tyr
Ala Cys Tyr Asn
Ala Asn Cys Tyr
Ala Asn Tyr Cys
Ala Tyr Cys Asn
Ala Tyr Asn Cys
Cys Ala Asn Tyr
Cys Ala Tyr Asn
Cys Cys Met Asn
Cys Cys Asn Met
Cys Phe Asn Ser
Cys Phe Ser Asn
Cys Gly Gln Tyr
Cys Gly Tyr Gln
Cys Met Cys Asn
Cys Met Asn Cys
Cys Asn Ala Tyr
Cys Asn Cys Met
Cys Asn Phe Ser
Cys Asn Met Cys
Cys Asn Ser Phe
Cys Asn Tyr Ala
Cys Gln Gly Tyr
Cys Gln Tyr Gly
Cys Ser Phe Asn
Cys Ser Asn Phe
Cys Tyr Ala Asn
Cys Tyr Gly Gln
Cys Tyr Asn Ala
Cys Tyr Gln Gly
Phe Cys Asn Ser
Phe Cys Ser Asn
Phe Asn Cys Ser
Phe Asn Ser Cys
Phe Ser Cys Asn
Phe Ser Asn Cys
Gly Cys Gln Tyr
Gly Cys Tyr Gln
Gly Gln Cys Tyr
Gly Gln Tyr Cys
N1-Demethylnicergoline
Gly Tyr Cys Gln
Gly Tyr Gln Cys
Met Cys Cys Asn
Met Cys Asn Cys
Met Asn Cys Cys
Asn Ala Cys Tyr
Asn Ala Tyr Cys
Asn Cys Ala Tyr
Asn Cys Cys Met
Asn Cys Phe Ser
Asn Cys Met Cys
Asn Cys Ser Phe
Asn Cys Tyr Ala
Asn Phe Cys Ser
Asn Phe Ser Cys
Asn Met Cys Cys
Asn Ser Cys Phe
Asn Ser Phe Cys
Asn Tyr Ala Cys
Asn Tyr Cys Ala
Gln Cys Gly Tyr
Gln Cys Tyr Gly
Gln Gly Cys Tyr
Gln Gly Tyr Cys
Gln Tyr Cys Gly
Gln Tyr Gly Cys
Ser Cys Phe Asn
Ser Cys Asn Phe
Ser Phe Cys Asn
Ser Phe Asn Cys
Ser Asn Cys Phe
Ser Asn Phe Cys
Tyr Ala Cys Asn
Tyr Ala Asn Cys
Tyr Cys Ala Asn
Tyr Cys Gly Gln
Tyr Cys Asn Ala
Tyr Cys Gln Gly
Tyr Gly Cys Gln
Tyr Gly Gln Cys
Tyr Asn Ala Cys
Tyr Asn Cys Ala
Tyr Gln Cys Gly
Tyr Gln Gly Cys
3-(2-BROMO-2-ETHOXYCARBONYL-VINYL)-2-PHENYL-INDOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
6-methoxy-3-methyl-2-[3-methyl-3-(4-nitrophenyl)triazen-1-yl]benzothiazolium methyl sulphate
1-[2-[[4-[(2-chloro-4-nitrophenyl)azo]phenyl]ethylamino]ethyl]pyridinium acetate
b-D-Galactopyranoside,4-nitrophenyl, 2,3,4,6-tetraacetate
Dacomitinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
fmoc-(s)-3-amino-4-(2-trifluoromethyl-phenyl)-butyric acid
Fmoc-(S)-3-Amino-4-(4-trifluoromethylphenyl)-butyric acid
Fmoc-(R)-3-amino-4-(2,4-dichloro-phenyl)-butyric acid
Fmoc-(R)-3-Amino-4-(2-trifluoromethylphenyl)-butyric acid
Fmoc-(R)-3-Amino-4-(4-trifluoromethyl-phenyl)-butyric acid
Fmoc-(S)-3-amino-4-(3,4-dichloro-phenyl)-butyric acid
Fmoc-(S)-3-Amino-4-(3-trifluoromethylphenyl)-butyric acid
(6R)-3,8-dioxo-7t-(2-phenyl-acetylamino)-(6rH)-5-thia-1-aza-bicyclo[4.2.0]octane-2ξ-carboxylic acid 4-nitro-benzyl ester
a-D-Galactopyranoside,4-nitrophenyl, 2,3,4,6-tetraacetate
4-nitrophenyl tetra-o-acetyl-beta-d-glucopyranoside
(2R,3S,4R,5R)-2-(hydroxyMethyl)-5-(6-((2-(Methylthio)ethyl)aMino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
fmoc-(r)-3-amino-4-(3,4-dichloro-phenyl)-butyric acid
Fmoc-(R)-3-Amino-4-(3-trifluoromethylphenyl)-butyric acid
2-(2-phenyl-9H-carbazol-9-yl)dibenzo[b,d]thiophen-4-ylboronic acid
fmoc-(s)-3-amino-4-(2,4-dichloro-phenyl)-butyric acid
4-[(4-Chlorophenyl)-2-pyridylmethoxy]piperidine p-nitrobenzoic acid salt
Voruciclib
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent D000970 - Antineoplastic Agents
(E)-N-(4-(3-(tert-Butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide
Sofpironium bromide
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent Sofpironium bromide (BBI 4000) is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium bromide reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium bromide also has a high afnity for the M1, M2, M4 and M5 subtypes[1].
CID 54733074
N-(1,3-benzodioxol-5-yl)-2-[[3-(2-methoxyphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]acetamide
3-fluoro-N-[4-[[4-(4-methoxyphenyl)-1-piperazinyl]-oxomethyl]phenyl]benzenesulfonamide
3-(4-{2-[2-(2-Bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid
(4as,4br,10bs,12as)-12a-Methyl-1,3-Dioxo-2-(Pyridin-3-Ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-Dodecahydronaphtho[2,1-F]isoquinolin-8-Yl Sulfamate
(2s,4s,5r)-2-Isobutyl-5-(2-Thienyl)-1-[4-(Trifluoromethyl)benzoyl]pyrrolidine-2,4-Dicarboxylic Acid
(2R)-2-[(1R)-1-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-2-oxoethyl]-5-methylidene-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
Methyl 2-[3-methoxy-2-[(5-phenyl-1,2-oxazole-3-carbonyl)amino]phenyl]-1,3-benzoxazole-4-carboxylate
2-[(4-{[([1,1-Biphenyl]-4-yl)methyl]amino}-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
(2S)-2-[[[4-[(2-amino-4-oxo-3H-quinazolin-6-yl)methyl-formylamino]phenyl]-hydroxymethyl]amino]pentanedioic acid
6-[3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoyloxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
[5-(4-Fluorophenyl)-7-(trifluoromethyl)-2-pyrazolo[1,5-a]pyrimidinyl]-[2-(3-pyridinyl)-1-piperidinyl]methanone
3-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoic acid (4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl) ester
[2-[2-(4-chlorophenyl)sulfanylanilino]-2-oxoethyl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
(4-oxo-2,3-dihydro-1H-cyclopenta[c]chromen-7-yl) 4-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoate
[2-(2-Methylpropylcarbamoylamino)-2-oxoethyl] 3-[(3,4-difluorophenyl)sulfonylamino]benzoate
N-(3-Methoxy-pyrazin-2-yl)-4-[3-(3-phenyl-acryloyl)-thioureido]-benzenesulfonamide
3-{[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl}benzimidazo[1,2-c]quinazoline-6(5H)-thione
7-(4-chlorophenyl)-4-(2-fluorophenyl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxylic acid 2-methoxyethyl ester
10-(2-Amino-ethylamino)-9-(3-chloro-phenyl)-2,2,5-trimethyl-1,4-dihydro-2H,9H-3-oxa-7-thia-6,9,11-tria za-benzo[c]fluoren-8-one
N-(2-fluorophenyl)-2-[[7-(2-fluorophenyl)-1,3-dimethyl-2,4-dioxo-5-pyrimido[4,5-d]pyrimidinyl]thio]acetamide
dihydroascorbigen 5-O-beta-D-glucoside
A dihydroascorbigen hexoside in which the hexoside component is a beta-D-glucosyl residue attached at position 5 via a glycosidic bond.
N-(2,6-dimethoxy-4-pyrimidinyl)-4-[(4-phenyl-2-thiazolyl)amino]benzenesulfonamide
butanoic acid [(4aS,5R,6R,7aR)-2-hydroxy-2-oxo-6-[6-(1-oxobutylamino)-9-purinyl]-4a,5,6,7a-tetrahydro-4H-furo[2,3-d][1,3,2]dioxaphosphorin-5-yl] ester
1-[(1R)-1-(benzenesulfonyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
2-methoxyethyl (4S,7S)-7-(4-chlorophenyl)-4-(2-fluorophenyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate
6-amino-N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxyquinolin-6-yl}hexanamide
methyl (2S)-2-[[(2Z)-2-(3,5-dioxo-4-phenyloxolan-2-ylidene)-2-phenylacetyl]amino]-3-phenylpropanoate
[(4aR,5R,6R,7aR)-6-[6-(butanoylamino)purin-9-yl]-2-hydroxy-2-oxo-4a,5,6,7a-tetrahydro-4H-furo[2,3-d][1,3,2]dioxaphosphinin-5-yl] butanoate
butanoic acid [(4aS,6S,7S,7aS)-2-hydroxy-2-oxo-6-[6-(1-oxobutylamino)-9-purinyl]-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphorin-7-yl] ester
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[2-(hydroxymethyl)-3-oxo-1-phenylpropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(3-hydroxyphenyl)-2-methyl-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(2-hydroxy-3-oxo-1-phenylbutyl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
(2S)-2-azaniumyl-5-{[(2R)-1-[(carboxylatomethyl)amino]-1-oxo-3-{[(2-phenylethyl)carbamothioyl]sulfanyl}propan-2-yl]amino}-5-oxopentanoate
oxolan-2-ylmethyl 4-(6-chloro-4-oxochromen-3-yl)-2-methyl-5-oxo-4a,6,7,8-tetrahydro-4H-quinoline-3-carboxylate
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(4-hydroxyphenyl)-2-methyl-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(2-hydroxy-2-methyl-3-oxo-1-phenylpropyl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1-hydroxy-2-methyl-3-oxo-1-phenylpropan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(2-hydroxyphenyl)-2-methyl-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1-hydroxy-3-oxo-1-phenylbutan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(4-methoxyphenyl)-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 3-fluorobenzoate
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 4-fluorobenzoate
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-fluorobenzoate
[(2S,3S,5R,6R)-2,3,5,6-tetrahydroxy-4-[(2S,3R,4S,5S)-3,4,5-trihydroxytetrahydropyran-2-yl]oxy-cyclohexyl] 2-(1H-indol-3-yl)acetate
(4-Methoxybenzyl)thiocarbamic acid 4-O-(tri-O-acetyl-alpha-L-rhamnopyranoside)
Inauhzin
Inauhzin is a dual SirT1/IMPDH2 inhibitor, and acts as an activator p53, used in the research of cancer.
(2s,3r,4s)-4-{[(2r,3s,5s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2h,3h,4h,4ah,9h-[1,3]dioxolo[4,5-j]phenanthridine-2,3,6,7-tetrol
(3s,4r,5s)-3,4-dihydroxy-5-[(1s)-2-hydroxy-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl]-3-(1h-indol-3-ylmethyl)oxolan-2-one
10-Formylfolic acid
-